Serum inhibitory factor 1, high-density lipoprotein and cardiovascular diseases

Current Opinion in Lipidology
Laurent O MartinezBertrand Perret

Abstract

The atheroprotective properties of HDL are supported by epidemiological and preclinical research. However, the results of interventional trials paradoxically indicate that drugs increasing HDL-cholesterol (HDL-C) do not reduce coronary artery disease (CAD) risk. Moreover, Mendelian randomization studies have shown no effect of HDL-C-modifying variants on CAD outcome. Thus, the protective effects of HDL particles are more governed by their functional status than their cholesterol content. In this context, any successful clinical exploitation of HDL will depend on the identification of HDL-related biomarkers, better than HDL-C level, for assessing cardiovascular risk and monitoring responses to treatment. Recent studies have enlightened the role of ecto-F1-ATPase as a cell surface receptor for apoA-I, the major apolipoprotein of HDL, involved in the important metabolic and vascular atheroprotective functions of HDL. In the light of these findings, the clinical relevance of ecto-F1-ATPase in humans has recently been supported by the identification of serum F1-ATPase inhibitor (IF1) as an independent determinant of HDL-C, CAD risk and cardiovascular mortality in CAD patients. Serum IF1 measurement might be used as a novel HDL-relat...Continue Reading

References

Sep 1, 1995·Arteriosclerosis, Thrombosis, and Vascular Biology·B F Asztalos, P S Roheim
Feb 1, 1997·The Journal of Clinical Investigation·S J Robins, J M Fasulo
Jun 1, 2000·The Journal of Biological Chemistry·E CabezonJ E Walker
Jun 6, 2000·Biochimica Et Biophysica Acta·D W Green, G J Grover
Sep 5, 2001·Nature Reviews. Molecular Cell Biology·M YoshidaT Hisabori
Aug 19, 2003·Nature Structural Biology·Elena CabezónJohn E Walker
Apr 6, 2005·Biochemical and Biophysical Research Communications·Paulina Cortés-HernándezJosé J García
Oct 19, 2005·Cellular and Molecular Life Sciences : CMLS·S JacquetR Barbaras
Oct 3, 2006·Atherosclerosis·Lewis H KullerUNKNOWN Multiple Risk Factor Intervention Trial Research Group
Feb 28, 2007·Circulation·David A Morrow, James A de Lemos
Sep 14, 2007·Journal of Bioenergetics and Biomembranes·Stefania ContessiIrene Mavelli
Sep 28, 2007·The New England Journal of Medicine·Philip BarterUNKNOWN Treating to New Targets Investigators
Jul 2, 2008·Cell Metabolism·Michelangelo CampanellaMichael R Duchen
Dec 17, 2008·American Heart Journal·Michal BenderlyUri Goldbourt
Jan 21, 2009·Annals of Internal Medicine·Karim El HarchaouiS Matthijs Boekholdt
Apr 18, 2009·Arteriosclerosis, Thrombosis, and Vascular Biology·Claudia RadojkovicLaurent O Martinez
Dec 5, 2009·American Heart Journal·Gregory G SchwartzUNKNOWN dal-OUTCOMES Committees and Investigators
Feb 25, 2010·Journal of Bioenergetics and Biomembranes·Valentina GiorgioGiovanna Lippe
Jul 24, 2010·Basic Research in Cardiology·Katherine J E SattlerBodo Levkau
Sep 8, 2010·Biochimica Et Biophysica Acta·Daniël BlomOscar Puig
Sep 11, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Aurélie C FabreLaurent O Martinez
Jan 14, 2011·The New England Journal of Medicine·Amit V KheraDaniel J Rader
Jun 28, 2011·The Journal of Clinical Investigation·Christian BeslerUlf Landmesser
Aug 20, 2011·Current Cardiovascular Risk Reports·Alanna Strong, Daniel J Rader
Oct 8, 2011·Arteriosclerosis, Thrombosis, and Vascular Biology·Clara CavelierArnold von Eckardstein
Nov 17, 2011·The New England Journal of Medicine·William E BodenWilliam Weintraub
Mar 31, 2012·Nutrition & Metabolism·Wijtske Annema, Uwe Jf Tietge
Apr 28, 2012·Circulation·Sarah ParishUNKNOWN Heart Protection Study Collaborative Group
Jun 9, 2012·Cardiovascular Research·Alexander W LohmanBrant E Isakson
Oct 12, 2012·The Journal of Biological Chemistry·Aline Kowalski-ChauvelCatherine Seva

❮ Previous
Next ❯

Citations

Sep 4, 2020·Current Opinion in Lipidology·Laurent O MartinezAnnelise Genoux
Mar 7, 2021·Hormone Molecular Biology and Clinical Investigation·Maurizio DelvecchioAntonio Gnoni
Nov 20, 2019·The American Journal of Cardiology·Frédéric BouissetJean Ferrières

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.